It is hard to be too critical of Novo Nordisk (NYSE: NVO )
, as this Danish biopharma specialist practically mints money with its
leading franchises in diabetes, hemophilia, and growth hormones. The
company is facing more challenges than it has in the past, though, as
biosimiliars and new formulations threaten to change the insulin market
and reimbursement pressures become more visible. It is hard to call Novo
Nordisk underpriced, but a stock that looks poised to generating
market-matching returns behind the security of good economic moats does
have some appeal on a risk-adjusted basis.
Continue here:
Are Investors Putting Too Much Faith In Novo Nordisk?
No comments:
Post a Comment